Subject: comorbidities
Subject: chronic lymphocytic leukemia
Subject: elderly
Subject: treatment
Year: 2020
Type: Article
Title: CIRS-G score as a rapid way to determine the overall multimorbidity burden and to select optimal and individualized therapy in newly diagnosed eldery CLL patients
Author: Gazmend Amzai
Author: Oliver Karanfilski
Author: Sonja Genadieva-Stavric
Author: Tatjana Sotirova
Author: Slobodanka Trpkovska Terzieva
Author: Marica Pavkovic
Author: Dijana Milovska
Author: Argjent Mucha
Author: Bozidar Kocoski
Author: Milce Cvetanoski
Author: Aleksandar Stojanovic
Abstract: Introduction. Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disorder in the elderly population. Many of these patients have multiple comorbidities, which might influence the choice of an adequate upfront chemoimmunotherapy option. The Cumulative Illness Rating Scale for Geriatrics (CIRS-G) score seems to be a reliable tool for assessment of the burden of comorbidity in elderly cancer patients. Objectives. The primary objective of our study was to assess the distribution of CIRS score status in CLL patients in real clinical practice. The secondary objective was to analyze which treatment option was used, and the effects it produced in each patients’ group, classified according to the CIRS score. Methods. In our prospective, single-center study, we focused on CLL patients that were referred to the University Clinic for Hematology in Skopje between 2017 and 2019. Comorbidity was assessed by the CIRS-G score in all patients included in our study (n=56) prior to the process of deciding on the most adequate treatment option. Results. The median age was 69 (±9.4) years. Comorbidities were identified in 80.4% of the study population, with an average CIRS score of 3.9. The three most common comorbidities were related to involvement of the vascular system (41.1%), endocrine-metabolic disorders (32.1%), and respiratory system disorders (17.9%). Only 16.1% of the patients had only 1 affected organ or system, other than hematological issues, while 64% of the patients had ≥2 affected systems. In 33.9% of the study patient cohort, the watch and wait initial approach was the standard of care. We considered 66.1% of patients to be requiring treatment, as follows: chemotherapy (chlorambucil, fludarabine+cyclophosphamide, bendamustine) only (30.4%), rituximab-based therapy (33.9%), and 1.8% of patients, due to the high comorbidity burden, were eligible only for supportive care. There was a stable trend of correlation between the CIRS score assessment and the treatment option prescribed (rs=0.7188, p<0.000001). Conclusions. The comorbidity status is a major consideration when treating elderly patients with CLL. Our study shows that comorbidity is quite a common feature in CLL patients and that it is increasing with age. CIRS is helpful in identifying the best treatment combination for the patients, that will enhance achieving long-term control of CLL, maintaining an optimal quality of life level.
Publisher: Македонско лекарско друштво = Macedonian Medical Association
Relation: Македонски медицински преглед = Macedonian Medical Review
Identifier: oai:repository.ukim.mk:20.500.12188/11502
Identifier: Gazmend Amzai, Oliver Karanfilski, Sonja Genadieva-Stavric, Tatjana Sotirova, Slobodanka Trpkovska Terzieva, Marica Pavkovic, Dijana Milovska, Argjent Muca, Bozidar Kocoski, Milce Cvetanoski and Aleksandar Stojanovic. CIRS-G score as a rapid way to determine the overall multimorbidity burden and to select optimal and individualized therapy in newly diagnosed eldery CLL patients. Mac.Med.Review 2020; 74(2): 94-98.
Identifier: 0025-1097
Identifier: http://hdl.handle.net/20.500.12188/11502
